SK96296A3 - Application of combination of gonadotropin releasing hormone analog with antiprogestin for the preparation of drug - Google Patents

Application of combination of gonadotropin releasing hormone analog with antiprogestin for the preparation of drug Download PDF

Info

Publication number
SK96296A3
SK96296A3 SK962-96A SK96296A SK96296A3 SK 96296 A3 SK96296 A3 SK 96296A3 SK 96296 A SK96296 A SK 96296A SK 96296 A3 SK96296 A3 SK 96296A3
Authority
SK
Slovakia
Prior art keywords
antiprogestin
treatment
releasing hormone
administration
gonadotropin releasing
Prior art date
Application number
SK962-96A
Other languages
English (en)
Slovak (sk)
Inventor
Gary D Hodgen
Robert F Williams
Daniel Grow
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of SK96296A3 publication Critical patent/SK96296A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SK962-96A 1994-02-04 1995-02-02 Application of combination of gonadotropin releasing hormone analog with antiprogestin for the preparation of drug SK96296A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions
PCT/US1995/001479 WO1995020972A1 (en) 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions

Publications (1)

Publication Number Publication Date
SK96296A3 true SK96296A3 (en) 1997-07-09

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
SK962-96A SK96296A3 (en) 1994-02-04 1995-02-02 Application of combination of gonadotropin releasing hormone analog with antiprogestin for the preparation of drug

Country Status (29)

Country Link
US (1) US5681817A (bg)
EP (1) EP0785792B1 (bg)
JP (1) JP3130048B2 (bg)
KR (1) KR970700507A (bg)
CN (1) CN1144486A (bg)
AP (1) AP724A (bg)
AT (1) ATE179610T1 (bg)
AU (1) AU689229B2 (bg)
BG (1) BG62238B1 (bg)
BR (1) BR9506606A (bg)
CA (1) CA2182183C (bg)
CZ (1) CZ291709B6 (bg)
DE (1) DE69509544T2 (bg)
DK (1) DK0785792T3 (bg)
ES (1) ES2132645T3 (bg)
FI (1) FI963036A0 (bg)
GR (1) GR3030164T3 (bg)
HU (1) HUT74622A (bg)
LT (1) LT4182B (bg)
LV (1) LV11782B (bg)
MD (1) MD1432C2 (bg)
NZ (1) NZ281441A (bg)
OA (1) OA10777A (bg)
PL (1) PL178273B1 (bg)
RO (1) RO117420B1 (bg)
RU (1) RU2110274C1 (bg)
SK (1) SK96296A3 (bg)
TJ (1) TJ242B (bg)
WO (1) WO1995020972A1 (bg)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114655A (en) * 1994-07-22 2005-08-31 Hampton Roads Medical College USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
CA2306110A1 (en) 1997-10-17 1999-04-29 Mochida Pharmaceutical Co., Ltd. Therapeutic agent of uterine leiomyoma, containing dienogest as effective ingredient
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
KR100864547B1 (ko) * 1999-08-31 2008-10-20 바이엘 쉐링 파마 악티엔게젤샤프트 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2004512369A (ja) * 2000-10-30 2004-04-22 ユニバーシティ・オブ・チューリッヒ 尿失禁の治療のためのｇｎｒｈアナログ
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
ES2366654T3 (es) * 2005-02-17 2011-10-24 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. Biofosfonatos para tratar la endometriosis.
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
SI3263112T1 (sl) * 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
AU2008300199B2 (en) * 2007-09-20 2013-09-12 Lapidot Medical Import And Marketing Ltd Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
KR101585221B1 (ko) 2014-02-27 2016-01-13 권희완 지압대 겸용 지압 베개
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
ES2102397T3 (es) 1990-03-16 1997-08-01 Applied Research Systems Tratamiento de la enfermedad del ovario policistico.
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Also Published As

Publication number Publication date
PL315792A1 (en) 1996-12-09
BG100766A (bg) 1997-06-30
LV11782A (lv) 1997-06-20
CA2182183C (en) 2003-09-16
MD1432B2 (en) 2000-03-31
BG62238B1 (bg) 1999-06-30
CA2182183A1 (en) 1995-08-10
KR970700507A (ko) 1997-02-12
WO1995020972A1 (en) 1995-08-10
EP0785792A1 (en) 1997-07-30
MD1432C2 (ro) 2000-09-30
HU9601969D0 (en) 1996-09-30
AU1838695A (en) 1995-08-21
NZ281441A (en) 1999-09-29
HUT74622A (en) 1997-01-28
LV11782B (en) 1997-12-20
JP3130048B2 (ja) 2001-01-31
DE69509544T2 (de) 1999-09-02
RO117420B1 (ro) 2002-03-29
JPH09508418A (ja) 1997-08-26
EP0785792A4 (bg) 1997-07-30
CN1144486A (zh) 1997-03-05
AP9600840A0 (en) 1996-07-31
DE69509544D1 (de) 1999-06-10
US5681817A (en) 1997-10-28
TJ242B (en) 1999-11-24
LT4182B (en) 1997-06-25
CZ291709B6 (cs) 2003-05-14
GR3030164T3 (en) 1999-08-31
EP0785792B1 (en) 1999-05-06
FI963036A (fi) 1996-08-01
FI963036A0 (fi) 1996-08-01
RU2110274C1 (ru) 1998-05-10
AU689229B2 (en) 1998-03-26
ATE179610T1 (de) 1999-05-15
CZ210396A3 (en) 1997-05-14
DK0785792T3 (da) 1999-10-18
BR9506606A (pt) 1997-09-09
PL178273B1 (pl) 2000-03-31
ES2132645T3 (es) 1999-08-16
OA10777A (en) 2002-12-23
AP724A (en) 1999-01-18
LT96133A (en) 1997-01-27

Similar Documents

Publication Publication Date Title
SK96296A3 (en) Application of combination of gonadotropin releasing hormone analog with antiprogestin for the preparation of drug
Baerwald et al. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use
Felberbaum et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
US5468736A (en) Hormone replacement therapy
Broekmans GnRH agonists and uterine leiomyomas
Friedman Treatment of uterine myomas with GnRH agonists
RU2181598C2 (ru) Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения
JP4418102B2 (ja) ジエノゲストを有効成分とする子宮筋腫治療剤
BG106442A (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
UA51627C2 (uk) Відновлення тонічної секреції естрогену з яєчників для довгочасних схем лікування
SK101395A3 (en) Pharmaceutical anticonceptive agent and its use
Vanhie et al. Medical management of endometriosis
Bromer et al. Medical treatment options for leiomyomas
Monroe et al. Clinical investigations of the contraceptive and therapeutic potential of nafarelin
Barbieri CLINICAL BIOLOGY OF GONADOTROPIN RELEASING HORMONE
IL94411A (en) Compositions comprising an analog of melatonin in combination with progestogen and/or estrogen for effecting contraception